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Endothelin-1 (ET-1), a recognised vasoconstrictor peptide, has
been implicated in the growth regulation of several tumours. Its
actions are mediated via two receptor subtypes ETA and ETB
(Yanagisawa et al, 1988; Clozel and Clozel 1989; Clozel et al,
1992). Both receptors have a role in vasomotor control, although
only ETA appears to be involved in the mitogenic action of ET-1
(Ali et al, 2000a; Bagnato et al, 1997, 1999; Nelson et al, 1996;
Kitigawa et al, 1994). 
ET-1 stimulates proliferation in vitro of fibroblasts, renal
mesangial cells, smooth muscle and several tumour cell lines,
including colorectal cancer (Hirata et al, 1989; Kusuhara et al,
1989; Simonson et al, 1989; Shichiri et al, 1991; Ali et al, 2000a).
Immunohistochemical studies on breast and prostate cancer
demonstrate increased expression of ET-1, with patients exhibiting
elevated plasma levels of ET-1 (Kojima and Nihei, 1995; Nelson
et al, 1995). Other malignant tumours associated with increased
ET-1 plasma levels include pancreatic and hepatocellular carci-
nomas (Oikawa et al, 1994; Nakamuta et al, 1993). 
We have previously shown in a pilot study that patients with
colorectal cancer, with and without liver metastases, have elevated
plasma levels of ET-1 and that the peptide is overexpressed by
different cell types within colorectal liver metastases (Shankar et al,
1998). ET-1 binding sites in primary colorectal cancer are known to
be unregulated (Inigagi et al, 1992). Recently, we investigated
binding to receptor subtypes and showed specifically that ETA
receptors are overexpressed while ETB receptors are underex-
pressed in colorectal cancer tissue compared to normal colon (Ali
et al, 2000b). These results suggest ET-1 may play a paracrine or
autocrine role in the development of colorectal cancer both locally
and systemically. 
The purpose of this study is to explore the role of ET-1 in
colorectal cancer from three perspectives: firstly, to confirm in a
further series of observations the elevated plasma levels of ET-1 in
patients with colorectal cancer; secondly, to assess the expression
of ET-1 in primary colorectal cancer specimens using immunohis-
tochemistry; and finally to assess the effect of intraportally infused
ETA and ETB receptor antagonists on the growth of liver meta-
stases in an animal model. 
METHODS 
Assay for circulating ET-1 
Blood collection 
Three groups of patients were studied: Group 1—controls (n = 22),
group 2—patients with primary colorectal cancer without liver
metastases on CT scanning or at laparotomy (n = 39), group 3—
patients with liver metastases whose primary colorectal cancer had
already been resected (n = 26). Information was collected on
serum carcinoembryonic antigen (CEA) levels and Dukes stage,
for all patients. 
Patients with the following conditions—which are indepen-
dently associated with elevated ET-1 levels—were excluded;
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and Raynauds phenomenon. We have previously demonstrated that
elevated ET-1 plasma levels are not associated with endothelial
cell trauma (as determined by the plasma levels of thrombo-
modulin, a marker of endothelial cell integrity) and as such repre-
sent an increased production of ET-1 rather than a consequence of
tumour invasion and damage of adjacent blood vessels. 
All patients had a fasting venous specimen taken prior to surgery.
This was collected into precooled blood bottles containing ethylene
diamine tetraacetic acid. The specimens were then centrifuged in a
chillspin (4˚ for 15 min at 1000 g) and the plasma frozen at –70˚
within 1 h of collection. 
ET-1 radioimmunoassay 
Plasma ET-1 was measured by radioimmunoassay (RIA, Nichols
Institute Diagnostics Ltd, Saffron Walden, Essex, UK) according
to the manufacturer’s instructions. The anti ET-1 antibody had a
cross-reactivity of 67% with ET-2, 84% with ET-3, 2.6% with Big
ET-1, 5.3% with Big ET-2 and 0.2% with Big ET-3. Endothelin
concentrations were calculated by plotting the % bound against
log concentrations of known standards. 
Immunohistochemistry for ET-1 
Specimens of primary colorectal cancer and normal colonic tissue
(taken 10 cm away from the tumour) were collected at the time of
resection from 10 patients, fixed in neutral buffered formalin for
24 h and paraffin wax embedded. 
Sections were cut (5 µ m thick), dewaxed in xylene, rehydrated
through decreasing concentrations of ethanol and washed in Tris
Buffered Saline (TBS, 3 × 5 min). Sections were taken to water
and antigen unmasking was achieved by microwaving slides in
600 ml of citrate buffer (0.01 M, pH = 6), for 20 min (full power,
800 W). Hot buffer was flushed out with cold running water and
sections were transferred to the incubation chamber and washed
with TBS. The protocol for ET-1 staining was as follows: Tissue
endogenous peroxidase was blocked by incubating the sections for
10 min in 0.5% methanolic H2O2. Sections were washed in
running tap water and incubated in mouse monoclonal anti-ET-1
antibody for 1 h (1:100 in TBS, Department of Immunology,
University College London, UK, Ong et al, 1993; the antibody
cross-reacts with ET-2 and ET-3 (15%), but not big ET). The spec-
imens were washed again in TBS and incubated with rabbit anti-
mouse immunoglobulin for 35 min. Routine streptavidin-biotin
peroxidase complexing followed (Dako Ltd, Ely, UK) according
to the manufacturer’s instructions. For the final colour reaction,
freshly prepared 3,3 diaminobenzidine (DAB) solution incorpo-
rating 0.03% H2O2 was applied on the slides (10 min). DAB was
rinsed off with TBS and sections were washed in running tap
water. Nuclei were counterstained with haematoxylin (4 min),
dehydrated and mounted. 
Assessment of ET-1 antagonists in an animal model of
colorectal liver metastases 
In vivo protocol 
The animal model used for colorectal liver metastases has been
described in detail previously (Loizidou et al, 1991). The intention
of this component of the study was to assess the effect of intra-
portally inoculated antagonists to ETA and ETB on the develop-
ment of liver metastases when given at varying times after tumour
inoculation. Given the vasoconstricting effect of ET-1 primarily
mediated via ETA, application of ETA and mixed ETA/ETB antag-
onists lead to vasodilation and subsequent hypotension, while
application of the ETB antagonist lead to hypertension; as such the
doses of antagonists used in all arms of the study were those which
produced an approximate 20% change in systemic blood pressure
(confirmed in a small series of experiments in our lab). This level
of blood pressure change was arbitrarily chosen as the safety limit.
The study was contacted under a Home Office approved project
licence. 
Male Hooded Lister rats weighing between 250–300 g were
anaesthetised using halothane inhalation. A lower midline incision
was then made and a tributary of the ileocolic vein was cannulated.
All animals received a bolus injection of 1 × 106 MC28 syngeneic
tumour cells in 0.2 ml saline (the dose known to produce repro-
ducible tumour growth by 14 days, Loizidou et al, 1991). 
In the first arm of the study the effect of infusions of ET-1 antag-
onists 30 min after tumour inoculation were assessed. The animals
were divided into 5 groups (6 animals per group) and received;
BQ123 (Alexis Corporation, Nottingham, UK) an ETA antagonist,
PD142893 (Alexis Corporation) a nonselective ETA and ETB
antagonist, A-192621 an ETB receptor antagonist (kindly donated
by Abbott, Chicago, II, USA), saline only and saline plus an intra-
muscular injection of 0.1 mg/kg acepromazine, (National
Veterinary Supplies, Stroke-on-Trent, UK) a hypotensive agent
which acts as a control for the vascular effects of ET-1 antagonism.
Each antagonist was infused at a rate of 100 µ g/kg/min for 30 min. 
In the second arm of the study, the ileocolic vein was cannulated
after tumour cell inoculation was performed. A fine 2F gauge
portacath (Becton-Dickinson UK Ltd, Oxford, UK) was tunnelled
under the skin to the interscapular area. This allowed access to the
portal circulation without the need for a further laparotomy. The
animals were then divided into 4 groups (6 animals per group)
with infusions of agents given via the portal circulation on days 2,
4 and 6 after tumour innoculation. The infusions were adminis-
tered under halothane anaesthesia for 30 min, at the same rate as in
the previous study. The groups were; saline, BQ123, PD142893,
A-192621 and saline plus intramuscular acepromazine. 
Given that different passages of the same tumour produce
different degrees of percentage hepatic replacement with tumour,
in order to compare the different agents one animal from each
group received tumour from the same passage. This allowed
comparisons to be made between the animals in each of the groups
and was applied to both arms of the study. 
All animals were sacrificed 14 days after intraportal tumour
inoculation, the livers were harvested and the tumours dissected
out. Wet weights were obtained for uninvolved liver and for total
tumour, per animal. The percent hepatic replacement (PHR) with
tumour was calculated for every animal, by dividing tumour
weight by total liver (i.e., liver plus tumour) weight and then
multiplying by 100. Results were presented as ratios between
PHRs of experimental animals to PHRs of control animals. 
RESULTS 
Plasma levels of ET-1 
The plasma levels of ET-1 in the control group (age range 42–82
years, median age 59.5 years, 8 females and 14 males, n = 22) had
a mean of 2.75 pg/ml, (SD = 1.37). In the colorectal cancer group
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16 females and 23 males, n = 39) the mean ET-1 level was 3.9 pg/
ml, (SD = 1.4) and in the group of patients with liver metastases
(median age 55, range 46–75 years, 3 females and 23 males, n = 26)
the mean ET-1 level was 4.5 pg/ml (SD = 1.5), as illustrated in
Figure 1. There was a significant difference between the cancer
patients and the control group (P < 0.001 and P < 0.01 for the
metastases and primary cancer groups, respectively) whilst there
was no significant difference between the two groups of cancer
patients. 
In the colorectal cancer group without metastases, there were 3
Dukes A, 26 Dukes B, and 10 Dukes C patients with CEA levels
ranging from <1–43 (median = 2). All 26 patients with liver
metastases were classed as Dukes D, by definition, with CEA
levels recorded between <1–1650 (median = 11). No correlation
was found between ET-1 levels and serum CEA or Dukes stage. 
ET-1 Immunohistochemistry 
Five patients had Dukes B and 5 had Dukes C carcinomas (3
females and 7 males). ET-1 immunohistochemistry of control
tissue showed ET-1 present in the apical layer of colonic epithe-
lium in 5 of 10 patients studied, vascular endothelial cells and
surrounding stroma (Figure 2A). In the colorectal cancer speci-
mens there was strong expression of ET-1 in the cytoplasm of
epithelial cells, stroma and blood vessels, in all the tumour speci-
mens studied (Figure 2B). There was no correlation between
Dukes staging and intensity of staining. 
ET-1 antagonists 
Day 0 infusion group 
The only group which demonstrated a significant reduction in
tumour load compared to the saline control group (paired t-test) was
those animals which received BQ123, The mean ratio (compared to
the saline control group) was 0.64 ± 0.20, (P < 0.05, paired t-test). 
PD142893 gave a mean of 1.10 ± 0.9 (NS), A-192621 was 1.13
± 0.88 (NS) and the saline/acepromazine group was 1.4 ± 0.70
(NS). These results are illustrated in Figure 3, which demonstrates
reductions in tumour load compared to the saline only group. 
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Figure 1 Levels of ET-1 in plasma from patients with or without colorectal
cancer. Individual values are shown for controls (   , n = 22), patients
with primary colorectal cancer (   , n = 39), and patients with previously
removed primary colorectal cancer who have subsequently developed liver
metastases (   , n = 26). Bars are means ( ± SD). Significance was reached
with both patient groups compared to controls (P < 0.01, Mann–Whitney test) 
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Figure 2 ET-1 immunoreactivity in colon. (A) Control: note ET-1 staining
(brown) limited to the apical segment of the colonic epithelium (arrows)
together with some staining of the stroma (S). (B) Colorectal cancer showing
strong staining for ET-1, in the cytoplasm of epithelial cancer cells (arrows)
and in the stroma (S). Counstertained with haematoxylin. Magnification × 700 
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Figure 3 Liver tumours in rats which received Endothelin receptor
antagonists. After tumour cell inoculation, animals received one of the
following: saline (controls    , dotted line), BQ123 (   ), PD142893 (   ), 
A-192621 (   ), or saline plus the hypotensive agent acepromazine (+) (n = 6
per group). Fourteen days later, liver tissue (tumour and normal) was
weighed. Results (Y-axis) are shown as a ratio of the % hepatic replacement
by tumour (PHR) in the experimental animals compared to control PHR. The
horizontal dotted line represents the average (mean) of control values 
(SD = 0.23). The BQ123 group had significantly smaller tumours than the
controls (P < 0.05, paired Student t-test)Day 2, 4 and 6 group 
In this group of experiments, none of the agents produced signifi-
cant reductions in tumour load compared to the control group. The
mean values (SD) were 1.11 ± 0.81 for BQ123, 1.02 ± 0.58 for
PD142893, and 1.80 ± 1.90 for the saline/acepromazine group. 
DISCUSSION 
ET-1 is a vasoconstrictor peptide the physiological functions of
which are well described. ET-1 acts via two G-linked protein
receptors ETA and ETB, with ETA mediating vasoconstriction and
ETB vasodilation (Yanasigawa et al, 1988; Clozel and Clozel,
1989; Clozel et al, 1992). 
Recently ET-1 has been implicated as a possible regulator of
tumour growth in a number of human malignancies including
colorectal cancer (Bagnato et al, 1997, 1999; Kojima and Nihei,
1995; Nelson et al, 1995, 1996, 1999; Oikawa et al, 1994; Nakamuta
et al, 1993; Shankar et al, 1998; Ali et al, 2000a). A variety of tumour
cell lines including colorectal cancer produce ET-1, which when
added to the growth medium results in an increase in tumour cell
turnover (Shichiri et al, 1991; Bagnato et al, 1997; Moraitis et al,
1977). Studies involving colorectal, ovarian and prostate cancer
suggest that the receptor responsible for the ET-1 mitogenic action
is ETA, which is probably upregulated (Bagnato et al, 1997, 1999;
Nelson et al, 1995; Ali et al, 2000a). Binding of ligand to receptor
usually activates phospholipase C followed by Ca++/protein kinase
C signalling. It has also been shown that ET-1 acts as a co-mitogen
with other factors such as epidermal growth factor, EGF (Bagnato
et al, 1997). Synergism might be in part explained by the fact that
Ca++/protein kinase C cross-talk with (activate) molecules
belonging to EGF-initiated tyrosine kinase cascades within the cell
(Bagnato et al, 1997; Luttrell et al, 1999). In a recent study (Eberl
et al, 2000), a mixed ETA/ETB receptor antagonist potentiated
FasL-induced apoptosis in cultured colorectal cancer cells. This
suggests that ET-1 may not only enhance growth, but also protect
against apoptosis in certain cell types. 
In colorectal cancer Inagaki et al (1992) demonstrated a high
density of ET-1 binding sites within tumour vessels and stromal
tissues surrounding primary colorectal cancers. Shankar et al
(1998) using immunoelectron microscopy have demonstrated
increased expression of ET-1 by a variety of cell types within
colorectal liver metastases and that patients with colorectal cancer
with and without liver metastases had elevated plasma levels of
ET-1. Such findings suggest ET-1 may act by a paracrine/autocrine
mechnism in these tumours. 
This study has extended the earlier work with regard to elevated
plasma levels of ET-1 in patients with colorectal cancer (Shankar
et al, 1998) and also shows that primary tumours as well as liver
metastases produce ET-1. These findings complement recently
published data on Big ET-1, the precursor of ET-1, in colorectal
cancer (Simpson et al, 2000). The authors found significantly
higher plasma levels of Big ET-1 in patients with cancer compared
to controls and that tissues from colorectal cancer overexpress Big
ET-1, compared to controls. Immunohistochemically, we demon-
strated that in colorectal cancer tissue, cancer epithelial cells,
endothelial cells and stromal cells overexpress ET-1, compared to
normal colon. The fact that, in some cases, normal colonic mucosa
also expresses ET-1 suggests it may play a role in the control of
normal cell shedding and perhaps apoptosis as suggested by other
groups (Shichiri et al, 1998). It has been proposed that primary
tumours control the growth of distant metastases by the secretion
of a variety of messenger compounds (Hanahan and Folkman,
1998) and ET-1 may have such a role. 
During the metastatic cascade, tumour emboli are shed from
primary colorectal cancers and reach the liver via the portal circu-
lation. These micrometastases initially obtain their blood supply
from the portal vein. This is the basis for the rationale behind peri-
operative portal vein chemotherapy (Shankar et al, 1996). 
Since ET-1 appears to play a role in colorectal cancer develop-
ment, administration of intraportally infused ET-1 antagonists at
this micrometastatic phase might produce a reduction in hepatic
tumour load. We have previously shown that MC28 tumours
possess similar anatomical and physiological profiles to colorectal
liver metastases and also express elevated levels of ET-1 (Loesch
et al, 1997; Ashraf et al, 1997). As such, the behaviour of these
tumours should mimic those of colorectal cancer. 
The findings in this study confirm the potential involvement of
ETA receptors in the development of colorectal liver metastases.
Only the ETA antagonist BQ123 produced a significant reduction
in tumour weight. Also of interest is the timing of delivery; since
only BQ123 given at the time of inoculation, but not if adminis-
tered at 2, 4, or 6 days after tumour inoculation, produced any
effect. These findings are in keeping with previous studies
involving cytotoxic portal vein infusions designed to prevent
hepatic tumour development, and suggest the importance of peri-
inoculation infusions compared to “delayed” treatment (Sutanto-
Ward et al, 1992). One explanation for this finding is that after
24–48 h these tumours may switch their blood supply from the
portal vein to the hepatic artery and hence insufficient antagonist
reaches the tumour. Another suggestion is that the role of ET-1 in
metastatic development is to promote tumour implantation and the
initial establishment of micrometastases, Accordingly, the admin-
istration of these antagonists after this stage would have little
effect. Further experimentation with different antagonists and
different in vivo models would be necessary to elucidate possible
mechanisms of action. Use of recently reported ETA antagonists
that could be delivered systemically (or orally) may resolve this
issue (Liu et al, 1998; Wilson et al, 1999). 
The absence of any effect in the hypotensive control group
suggests that changes in blood flow caused by ET-1 receptor
antagonism are not the cause of the effect seen. 
These results suggest that ET-1 is produced by colorectal
cancer, and may play a role both locally and systemically in cancer
development by acting through ETA receptors. In addition applica-
tion of ETA antagonists via the portal vein at the time of tumour
implantation reduces subsequent hepatic involvement in this
model of colorectal liver metastases. 
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